Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Remains Focused On Cosmetics Carrying Drug Claims – OCAC Director

Executive Summary

At the American Conference Institute’s Legal, Regulatory and Compliance Forum on Cosmetics, FDA Office of Cosmetics and Colors Director Linda Katz discussed her division’s priorities for the year. On the enforcement front, OCAC will continue to focus on cosmetic products marketed with drug claims, she said.

Advertisement

Related Content

Audio Feature: FDA Monitoring Cosmetic Claims, But Litigation Remains Biggest Threat
FDA Shows Skin Authority Who’s Boss With Warning For Drug Claims
FDA Warns Former AAD President For DNA Eye Renewal Claims
FDA Reports ‘Proliferation’ Of Cosmetics Making Drug Claims
FDA Cautions Consumers On Cosmetics Carrying Drug Claims
Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning
Will Cosmeceutical Pioneer Turn Its Wagons Around? FDA Warns Strivectin
FDA Warning To L’Oreal Creates Uncertainty For Anti-Redness, Dark Spot Treatments
‘Revolution’ Quelled? FDA Warns Firm For ReLuma Stem-Cell Claims
Advertisement
UsernamePublicRestriction

Register

RS019398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel